Bempedoic acid is a cholesterol-lowering medication classified as a lipid-modifying agent. It is available as a 180 mg oral pill and requires a prescription in Hong Kong. The drug is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in adults with hypercholesterolemia, either as an addition to maximally tolerated statin therapy or as an alternative for patients who cannot tolerate statins. In Hong Kong, the Department of Health oversees its regulatory status, and the medication is listed in the Hong Kong Pharmaceutical Registry as a prescription-only product.
Bempedoic acid inhibits the enzyme ATP citrate lyase (ACL), a key step in the hepatic synthesis of cholesterol that lies upstream of HMG-CoA reductase, the target of statins. By blocking ACL, the drug reduces the production of acetyl-CoA, thereby decreasing the amount of cholesterol that can be generated in the liver. The resulting decline in intra-hepatic cholesterol triggers an up-regulation of low-density lipoprotein (LDL) receptors, which enhances the clearance of LDL-cholesterol (LDL-C) from the bloodstream.
Onset of LDL-C reduction is typically observed within two weeks of daily dosing, with maximal effect reached after about six weeks. The drug has a plasma half-life of roughly 21 hours, allowing for once-daily administration. Bempedoic acid is a pro-drug that is activated in the liver by very-long-chain acyl-CoA synthetase-1 (ACSVL1), a process that limits its activity in skeletal muscle and helps reduce the risk of muscle-related side effects compared with statins.
In Hong Kong, the use of bempedoic acid follows the same indications approved by the FDA and EMA. Treatment decisions are guided by the local cholesterol management guidelines published by the Hong Kong Cardiology Society, which recommend LDL-C targets based on cardiovascular risk stratification.
This article provides educational information about bempedoic acid and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Bempedoic acid is designed to complement or substitute statins when statins are not tolerated, but it does not provide the same magnitude of LDL-C reduction as high-intensity statins. Most clinicians use it as part of a combination therapy to achieve guideline-recommended lipid targets.
Report the symptom to your healthcare provider promptly. The clinician may check creatine kinase levels and consider adjusting the dose of any concurrent statin or switching to an alternative lipid-lowering agent.
Current data do not require dose adjustment for mild to moderate renal impairment, but patients with severe kidney disease should discuss potential risks with their physician, as limited studies are available.
The medication can raise serum uric acid, potentially triggering gout attacks in susceptible individuals. Regular monitoring of uric acid levels and prophylactic use of gout-preventive therapy may be advisable.
Yes, bempedoic acid is a prescription medication, so you should carry it in its original container with a copy of the prescription. Check the destination country’s import regulations, especially for Hong Kong residents traveling abroad.
No specific diet is mandated, but maintaining a heart-healthy eating pattern (low saturated fat, high fiber) enhances overall cholesterol management and supports the drug’s efficacy.
Certain herbal products, such as St. John’s wort, can induce liver enzymes that might alter drug metabolism. While bempedoic acid is not a major CYP substrate, it is prudent to disclose all supplements to your clinician.
Bempedoic acid reduces cholesterol synthesis in the liver, whereas PCSK9 inhibitors are monoclonal antibodies that increase LDL-receptor recycling, leading to greater LDL-C reductions. PCSK9 inhibitors are administered via injection and are generally reserved for patients with very high risk or those who cannot achieve targets with oral agents.
Baseline testing is recommended, followed by a repeat assessment at about 4 weeks. If results remain normal, periodic monitoring every 3-6 months is typical, or sooner if symptoms suggest liver injury.
Safety in pregnancy and lactation has not been established. The drug should be avoided, and alternative lipid-lowering strategies should be discussed with a healthcare professional.
